company background image
BRNS logo

Barinthus Biotherapeutics NasdaqGM:BRNS Stock Report

Last Price

US$2.38

Market Cap

US$90.7m

7D

-1.2%

1Y

3.5%

Updated

28 Mar, 2024

Data

Company Financials +

Barinthus Biotherapeutics plc

NasdaqGM:BRNS Stock Report

Market Cap: US$90.7m

BRNS Stock Overview

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.

BRNS fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Barinthus Biotherapeutics plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Barinthus Biotherapeutics
Historical stock prices
Current Share PriceUS$2.38
52 Week HighUS$5.10
52 Week LowUS$1.64
Beta-0.48
1 Month Change-15.15%
3 Month Change-35.50%
1 Year Change3.48%
3 Year Changen/a
5 Year Changen/a
Change since IPO-83.12%

Recent News & Updates

Recent updates

We Think Vaccitech (NASDAQ:VACC) Can Afford To Drive Business Growth

Jul 07
We Think Vaccitech (NASDAQ:VACC) Can Afford To Drive Business Growth

Vaccitech's (NASDAQ:VACC) Earnings Are Of Questionable Quality

Nov 17
Vaccitech's (NASDAQ:VACC) Earnings Are Of Questionable Quality

Vaccitech promotes Gemma Brown to CFO

Sep 20

Analysts Just Made An Incredible Upgrade To Their Vaccitech plc (NASDAQ:VACC) Forecasts

Aug 15
Analysts Just Made An Incredible Upgrade To Their Vaccitech plc (NASDAQ:VACC) Forecasts

Vaccitech plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 13
Vaccitech plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Vaccitech GAAP EPS of $0.41, revenue of $17.06M

Aug 09

Growth Investors: Industry Analysts Just Upgraded Their Vaccitech plc (NASDAQ:VACC) Revenue Forecasts By 51%

May 19
Growth Investors: Industry Analysts Just Upgraded Their Vaccitech plc (NASDAQ:VACC) Revenue Forecasts By 51%

Vaccitech: Aiming For A Cure In Chronic Hepatitis B

Apr 03

Vaccitech: The Next Big Vaccine Trade

Jun 27

Vaccitech EPS misses by $0.69, beats on revenue

Jun 14

Shareholder Returns

BRNSUS BiotechsUS Market
7D-1.2%0.9%0.2%
1Y3.5%11.0%28.1%

Return vs Industry: BRNS underperformed the US Biotechs industry which returned 10.3% over the past year.

Return vs Market: BRNS underperformed the US Market which returned 28.8% over the past year.

Price Volatility

Is BRNS's price volatile compared to industry and market?
BRNS volatility
BRNS Average Weekly Movement7.0%
Biotechs Industry Average Movement11.7%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: BRNS's share price has been volatile over the past 3 months.

Volatility Over Time: BRNS's weekly volatility has decreased from 16% to 7% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2016107Bill Enrighthttps://www.barinthusbio.com

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company’s development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older.

Barinthus Biotherapeutics plc Fundamentals Summary

How do Barinthus Biotherapeutics's earnings and revenue compare to its market cap?
BRNS fundamental statistics
Market capUS$90.69m
Earnings (TTM)-US$73.35m
Revenue (TTM)US$802.00k

115.5x

P/S Ratio

-1.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BRNS income statement (TTM)
RevenueUS$802.00k
Cost of RevenueUS$44.87m
Gross Profit-US$44.07m
Other ExpensesUS$29.28m
Earnings-US$73.35m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.88
Gross Margin-5,495.26%
Net Profit Margin-9,145.51%
Debt/Equity Ratio0%

How did BRNS perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.